Quick poll
Closes 
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma
Latest Congress Coverage
Latest Biology
General MM,Relapsed/refractory patients
The gap between clinical trial and real-world practice outcomes in multiple myeloma
Nov 22, 2018
Latest Drug Updates
Relapsed/refractory patients
FDA Regenerative Medicine Advanced Therapy designation for P-BCMA CAR T-cell therapy
Nov 20, 2018
Relapsed/refractory patients
FDA approves elotuzumab in combination with pomalidomide and dexamethasone for…
Nov 8, 2018
,
Expert Opinion
Relapsed/refractory patients
FDA grants Orphan Drug Designation to STRO-001 for the treatment of multiple myeloma
Oct 17, 2018
Where we are next
60th ASH Annual Meeting & Exposition
December 1–4, 2018 | San Diego, CA
The meeting prides itself on bringing together professionals worldwide to highlight 'state-of-the-art clinical practice and the latest findings in hematology research'. The program covers all hematological indications, including multiple myeloma. Stay tuned to follow our first-hand ASH coverage.
#ASH18 #mmsm
Connect with us
Our sister hubs
Visit our other community physician education hubs in haematology and oncology
